Drugs / HX9428
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07185841 | Jul 2025 → Jul 2028 expected | wet macular degeneration | Fujian Haixi Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HX9428 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07185841 ↗ |
| Route | Oral | “Subjects will receive HX9428 orally every day.” NCT07185841 ↗ |